GovInfoSecurity

Health AI Firm Faces Lawsuits Over DNA Data Use, Disclosure

A healthcare artificial intelligence firm that sells genetic information from an acquired database holding the results of ...
Crain's Chicago Business

Tempus AI entering the immuno-oncology space

Tempus AI has an immunology risk testing product ready for researchers to test out and is working with Cleveland Clinic on better ways to assess how immunotherapy might work on patients. The ...
TMCnet

Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC, today announced a ...
Morningstar

Northwestern Medicine Selects Tempus to Expand Genomic Testing

Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient ...

Tempus AI (TEM) Unveils Cancer Test Kit, Soars 13.9%

Tempus AI Inc. (NASDAQ:TEM) is one of the 9 Stocks Stealing the Show. Tempus AI extended its winning streak to a 3rd straight ...
Crain's Chicago Business

Tempus scores a win with Blue Cross plans

Tempus announced this morning it has inked agreements for in-network provider status with Blue Cross Blue Shield health plans in six states, significantly enhancing its relationships with commercial ...
Nasdaq

Tempus Announces the National Launch of FDA-Approved xT CDx Test

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the ...
Nasdaq

Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2

New RNA-based algorithm is now available with the xR assay “This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep ...
Seeking Alpha

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its ...

Tempus AI Shares Gain on Commercial Partnership With Predicta Biosciences

Shares of Tempus AI rose after the medical technology company said it was expanding the commercial availability of whole-genome sequencing assay technology to detect and analyze cancer cells in ...
Business Wire

Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is ...